Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
Date:8/30/2010

ategy. We are now working towards an official response to the EMA Day 120 questions, due by the end of 2010.

As of today we remain confident in the approvability of Glybera(R). Our assessment is based on the following:

- Our response to the EMA does not require further clinical trials with additional new to be treated patients. We expect to be able to formulate our response satisfactorily by submitting data and further analyses from already treated patients. - More, highly relevant, data from our last clinical trial CT-AMT-011-02 AMT strongly suggest that Glybera's effects are lasting (one year) via a mechanism that causes clearance of chylomicrons, the fat carrying particles which are responsible for pancreatitis in LPLD patients. - Overall we have developed a clear response strategy, which, if executed with no unforeseen adverse events or delays, should allow us to remain on track for a positive EMA decision in the middle of 2011.

Hemophilia B

Further to their 2009 agreement to co-develop a vector-gene combination for the treatment of Hemophilia B, AMT and St. Jude Children's Research Hospital in the USA have successfully transferred Factor IX to AMT's manufacturing platform and have demonstrated proof of concept in animals in 2010. The multicenter, dose escalation study with this vector-gene combination began in March, 2010 at University College London Hospital in the United Kingdom guided by Prof. Amit Nathwani. The first patient has been dosed successfully and demonstrated good results both in terms of clinical benefit and side effects. Further enrolment of patients is expected in the second half of 2010.

Duchenne Muscular Dystrophy

In support of its program to treat Duchenne Muscular Dystrophy, AMT received an investment credit from SenterNovem (now Agentschap.nl), the Dutch government innovation agency, in January 2010. The credit comprises a loan covering 35% of the costs of the project through to 2013 with
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
2. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine
7. Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
8. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
9. VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
10. BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth
11. Brain-like computing on an organic molecular layer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink regimen ... They are the first functional focus beverage to give ... alternative to the temporary fix associated with energy drinks. ... 29, 2014, with hopes to raise $50,000 over the ... http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks were ...
(Date:7/23/2014)... SKOKIE, Ill. , July 23, 2014 ... acid (SNA™) constructs as gene regulatory and ... Snyder has joined AuraSense Therapeutics, executive ... July 11. Prior to joining ... President and Chief Financial Officer of Cellular ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
(Date:7/23/2014)... 23, 2014 Last year, Formedix ... a leading global provider of data management solutions for ... a leading-edge system for electronic data capture (EDC) and ... design and study execution tools added TrialMaster to its ... anticipated version of Transform for TrialMaster, is being released ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... physics of the perfect pizza toss and will use ... thinner that a human hair. , Mr Daniel (Kuang-Chen) ... Friend and Senior Lecturer Leslie Yeo, videotaped a professional ... Research Laboratory, then calculated how best to describe the ...
... WAYNE, Pa., April 27 Encorium Group, Inc. ... full-service multinational contract research organization (CRO) that provides design, ... registries to many of the world,s leading pharmaceutical companies, ... new business contracts, consisting of both new business contracts ...
... ", or "the Company") (OTC Bulletin Board: SNBP) is ... seven key patents from Company CEO Dr. Lequn Huang ... enhance Sinobiopharma,s ability to execute on its mission of ... for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/23/2014)... a high health risk warning for Yellowknife and surrounding ... to forest fires. In the image taken by ... normal wind patterns. Fire is an obvious health ... not quite so obvious and its effects are insidious. ... (forest, brush, crop, structure, tires, waste or wood burning) ...
(Date:7/23/2014)... , , , ... , , , , ... lifespan. The idea, they argue, would be to target the... , , ... , , , , ... , , , , , , , Medicine focuses almost entirely on ...
(Date:7/23/2014)... are disappearing, and though conservationists are examining several possible ... rain and light pollution, a key piece of the ... once they leave their breeding sites, and what threats ... answer this question, a team of researchers out of ... map produced for a songbird, using tracking from both ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2
... clinical trial, a new drug that selectively blocks ... acute kidney transplant rejection as cyclosporine, the standard ... experimental drug, a co-stimulatory blocker called belatacept (LEA29Y), ... of the toxic side effects associated with standard ...
... and chimpanzees both pass on "traditions" to other members ... feeding behaviour. The findings add to evidence that cultural ... involved killerwhales at Marineland in Niagara Falls in Ontario, ... to catch birds, and passed the strategy on to ...
... mast cells, known to play a central role in ... that can kill these cells by programming them to ... move researchers another step closer to understanding the life ... new treatments for allergy and inflammatory responses in arthritis, ...
Cached Biology News:New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4More animals join the learning circle 2Climate model links higher temperatures to prehistoric extinction 2
Calcium Channel alpha 2 delta-2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone 42, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
CBF-B (G-2)...
Biology Products: